Top Medical Stocks To Watch For 2023

Ventas, Inc. (VTR Quick QuoteVTR ) is likely to capitalize on the senior housing industry recovery, aided by a high-quality portfolio. However, reduced cash flow from the sale of assets, and competition from national and local operators might act as deterrents for the company.

In light of effective vaccine roll-outs, the company is seeing emerging positive senior living operations trends in the United States, with move-ins exceeding the pre-pandemic levels, while move-outs remain steady. In addition, the market for seniors housing and healthcare real estate is large and fragmented, offering a huge scope of consolidation. This, along with the ownership of top-quality senior housing assets in strategic markets, which enjoy stronger demographic trends, creates a solid opportunity for Ventas.

The company’s office segment, which includes medical office buildings (MOBs), academic medical and research & innovation (R&I) centers, is poised to gain from favorable demographics and growing outpatient trends. The R&I centers are essential for the delivery of crucial healthcare services and research related to life-saving vaccines and therapeutics. Ventas is driving its R&I business forward aided by ground-up developments and asset acquisitions, in a bid to capitalize on the growing healthcare-driven research. It owns R&I centers in notable life-science clusters of Cambridge, San Francisco and Maryland, with presence in more than 16 top-tier research university campuses.

Top Medical Stocks To Watch For 2023: Western Union Company (WU)

The Western Union Company provides money movement and payment services worldwide. The company operates in three segments: Consumer-to-Consumer, Consumer-to-Business, and Business Solutions. The Consumer-to-Consumer segment offers money transfer services. This segment provides various options for sending funds, including walk-in and online money transfer, as well as account based money transfer services through a network of third-party agents using multi-currency and real-time money transfer processing systems. The Consumer-to-Business segment offers options to make one-time or recurring payments from consumers to businesses and other organizations, including utilities, auto finance companies, mortgage servicers, financial service providers, government agencies, and other businesses. It also provides various products, which provide consumers choices as to the payment channel and method of payment, including Speedpay, Pago Fácil, and Western Union Payments. This segment offers its services primarily through the phone and Online, as well as through its agent networks and selected company-owned locations. The Business Solutions segment facilitates payment and foreign exchange solutions, primarily cross-border and cross-currency transactions for small and medium size enterprises and other organizations, as well as for individuals. This segment provides its services through the phone, partner channels, and the Internet. As of December 31, 2015, the company had a network of approximately 500,000 agent locations in approximately 200 countries and territories. The Western Union Company was incorporated in 2006 and is headquartered in Englewood, Colorado.

Advisors’ Opinion:

  • [By Logan Wallace]

    ILLEGAL ACTIVITY WARNING: “Rothschild & Co. Asset Management US Inc. Increases Position in IBERIABANK Corp (IBKC)” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at

  • [By Logan Wallace]

    Northern Trust Corp cut its holdings in shares of IBERIABANK Corp (NASDAQ:IBKC) by 35.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 743,718 shares of the bank’s stock after selling 401,090 shares during the period. Northern Trust Corp owned approximately 1.33% of IBERIABANK worth $56,374,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Stephan Byrd]

    IBERIABANK Corp (NASDAQ:IBKC) declared a quarterly dividend on Thursday, August 2nd, Zacks reports. Shareholders of record on Friday, September 28th will be paid a dividend of 0.39 per share by the bank on Friday, October 26th. This represents a $1.56 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date is Thursday, September 27th. This is a positive change from IBERIABANK’s previous quarterly dividend of $0.38.

  • [By Ethan Ryder]

    Credit Agricole S A lessened its holdings in IBERIABANK Corp (NASDAQ:IBKC) by 4.3% in the 2nd quarter, Holdings Channel reports. The firm owned 20,706 shares of the bank’s stock after selling 922 shares during the quarter. Credit Agricole S A’s holdings in IBERIABANK were worth $1,570,000 as of its most recent SEC filing.

Top Medical Stocks To Watch For 2023: Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Advisors’ Opinion:

  • [By Joseph Griffin]

    Svb Leerink assumed coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) in a research report released on Friday. The firm issued an outperform rating and a $165.00 price target on the biopharmaceutical company’s stock.

  • [By Cory Renauer]

    Any day now, Intercept Pharmaceuticals (NASDAQ:ICPT) will share long-awaited pivotal trial results that could make its Ocaliva drug the first approved NASH treatment. The lead candidate at Madrigal Pharmaceuticals (NASDAQ:MDGL) is behind Ocaliva on the development timeline, but results so far tick all the right boxes. Let’s examine the case for both stocks to decide which one is the better pick right now.

  • [By Brian Orelli]

    The data points are substantially better than Madrigal Pharmaceuticals’ (NASDAQ:MDGL) MGL-3196 scored earlier this year, with its 36.3% liver fat reduction and 60.3% of patients achieving a 30% reduction in liver fat. While it can be dangerous to compare drugs across clinical trials, since the companies don’t necessarily enroll the same types of patients, the placebo groups in the two trials performed remarkably similarly, with 18.4% and 18.2% of patients taking placebo in Madrigal’s and Viking’s studies, respectively, having at least a 30% reduction in liver fat.

  • [By Keith Speights]

    Viking and Madrigal Pharmaceuticals (NASDAQ:MDGL) both have thyroid receptor beta agonists. Madrigal reported positive phase 2 results in December 2017 for its lead candidate MGL-3196. The two biotechs appear to be top acquisition targets for bigger players seeking to bolster their NASH pipelines. But since Viking’s market cap is only one-third that of Madrigal’s, it would be the cheaper alternative for a major drugmaker to acquire — perhaps even Gilead.

Top Medical Stocks To Watch For 2023: Potlatch Corporation(PCH)

Potlatch Corporation operates as a real estate investment trust (REIT) that owns and manages timberlands located in Arkansas, Idaho, Minnesota and Wisconsin in the United States. The Resource Management Division manages its timberlands, harvests timber, procures other wood fiber, sells logs and leases land for hunting and other recreational activity. The Real Estate Division develops and sells land parcels, as well as invests in timberlands. The Wood Products Division manufactures lumber, plywood, and particleboard in Arkansas, Idaho, Michigan, and Minnesota. This segment’s products are sold to wholesalers primarily for use in home building and other construction activities. Potlatch was founded in 1903 and is headquartered in Spokane, Washington.

Advisors’ Opinion:

  • [By Stephan Byrd]

    Comerica Bank lifted its stake in shares of Potlatchdeltic Corp (NASDAQ:PCH) by 9.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,810 shares of the real estate investment trust’s stock after purchasing an additional 3,890 shares during the quarter. Comerica Bank owned about 0.07% of Potlatchdeltic worth $1,676,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Potlatchdeltic (PCH)

    For more information about research offerings from Zacks Investment Research, visit

Leave a Reply

Your email address will not be published.